Patents Assigned to QOOLABS, INC.
  • Publication number: 20210278403
    Abstract: The present disclosure relates to lateral flow test devices, and uses thereof, for assessing recombinant protein (polypeptide) expression or reporter gene expression in a sample. In some aspects, the present disclosure relates to the use of lateral flow immunoassay to quickly detect the expression of recombinant proteins. In some aspects, lateral flow immunoassay can be used for qualitative and/or quantitative analysis of the recombinant protein expression.
    Type: Application
    Filed: August 17, 2017
    Publication date: September 9, 2021
    Applicant: Qoolabs, Inc.
    Inventor: Hong Qi
  • Publication number: 20190023806
    Abstract: The present disclosure in some aspects relates to hemoglobin (including various hemoglobin variants) polypeptides. In some aspects, the present disclosure further relates to hemoglobin antibodies, including camelid antibodies that specifically bind to hemoglobin, and antibody fragments. The disclosure further relates to methods of detecting an analyte in a sample using a camelid antibody, such as a camelid VHH antibody or fragments thereof. In one aspect, provided herein is a technology platform for isolating highly specific antibodies and applying these antibodies in an immunoassay, such as a lateral flow immunoassay (LFIA). In some aspects, this technology is used to develop hemoglobin variant specific antibodies and to produce LFIA devices for rapid and early diagnosis of a disease.
    Type: Application
    Filed: October 20, 2016
    Publication date: January 24, 2019
    Applicant: QOOLABS, INC.
    Inventor: Hong QI
  • Publication number: 20180292408
    Abstract: The present disclosure in some aspects relates to HCV core antigen polypeptides. In some aspects, the present disclosure further relates to HCV antibodies, including camelid antibodies that specifically bind to HCV core antigen, and antibody fragments. The disclosure further relates to methods of detecting an analyte in a sample using a camelid antibody, such as a camelid VHH antibody or fragments thereof. In one aspect, provided herein is a technology platform for isolating highly specific antibodies and applying these antibodies in an immunoassay, such as a lateral flow immunoassay (LFIA). In some aspects, this technology is used to develop HCV core antigen specific antibodies and to produce LFIA devices for rapid and early diagnosis of HCV. In other aspects, a rapid test is provided for screening and detection of hepatitis C virus infection to improve the diagnosis rate and effectively prevent HCV infection transmission.
    Type: Application
    Filed: April 19, 2016
    Publication date: October 11, 2018
    Applicant: QOOLABS, INC.
    Inventor: Hong QI